Therapeutic Drug Monitoring Market: Current Analysis and Forecast (2022-20230)

The therapeutic drug monitoring market is expected to register a CAGR of approx. 10% over the period of 2022-2030. Therapeutic drug monitoring (TDM) measures drug concentrations in a patient's blood or other bodily fluids to maximize the efficacy and security of pharmacological therapy. TDM's purpose is to guarantee that a patient receives the correct medicine dose depending on individual characteristics such as age, weight, genetics, and other medical problems. TDM is commonly employed for medications with a narrow therapeutic range, which means there is a tiny gap between the drug's minimum effective concentration and hazardous concentration. Healthcare practitioners can alter the amount or frequency of delivery as needed to achieve the intended therapeutic benefit while minimizing the risk of unwanted effects by monitoring medication levels. The growing demand for therapeutic drug monitoring can be attributed to the rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular disease, etc. across the globe. For instance, according to the CDC, around 18 million Americans aged 20 and above have heart disease and nearly 650,000 Americans die of heart disease each year. Owing to the glaring statistics therapeutic drug monitoring help to reduce or optimize drug therapy in the patient suffering from chronic diseases such as cancer, diabetes, and cardiovascular disease, etc. which require long-term drug therapy which would contribute to the growth of the market in the forthcoming period as well. Furthermore, the therapeutic drug monitoring market is anticipated to grow on account of the increasing awareness among healthcare professionals. However, some of the restraints in the market, including the high cost of the equipment and stringent regulations are impeding the growth of this market all over the world.

Based on product type, the market is segmented into consumables and devices. Among them, the consumables segment captured a significant share of the market in 2021. This is due to the increasing prevalence of chronic diseases which is boosting this segment. Moreover, the increasing demand for new technology-based, cost-effective kits and the use of reagents in the R&D area is also boosting the growth of the segment of the market.

Based on the technology, the market is bifurcated into immunoassays, proteomic technologies, and others. Among them, the immunoassays segment is expected to grow at a higher CAGR in the market. This is due to the availability of highly specific and reliable immunoassay which is likely to aid the growth of the segment. Moreover, the rising adoption rate of advanced techniques and the requirement of minimal training to handle the equipment also boosted the growth of the segment.

Based on the drug class, the therapeutic drug monitoring market has been classified as anti-epileptics, antibiotics, immunosuppressants, psychoactive, and anti-arrhythmic drugs. Among them, the anti-epileptics category grabbed a considerable market share, and it is expected to grow at a significant CAGR during the forecast period. The increasing prevalence of epilepsy and seizures are the factors that help in boosting the segment. Moreover, the rising growth in the number of Anti-epileptic drugs is also likely to aid the segment growth.

Based on the end-user, the therapeutic drug monitoring market has been classified as hospital labs, private labs, and others. Among them, the hospital labs segment is expected to grow at a higher CAGR in the market. This is due to the availability of accurate patient information, such as age, metabolism, ethnicity, and drug performance history in the hospitals which boost the segment growth. Moreover, the increasing use of computerized entry of patient history and information records is more likely to boost the growth of the market segment.

For a better understanding of the market adoption of therapeutic drug monitoring, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), and Rest of World. Therapeutic drug monitoring has gained increasing popularity in North America due to various factors. The increasing prevalence of chronic diseases such as cancer, etc. is boosting the demand for the therapeutic drug monitoring market in this region. The growing demand for personalized medicine is becoming the highlight for TDM as it allows healthcare providers to tailor drug therapy to individual patients based on their unique pharmacokinetic and pharmacodynamics profiles. The advancement in technology is also attributed to the growth of the therapeutic drug monitoring market. For instance, In June 2020, Quest Diagnostics launched a new therapeutic drug monitoring test for the immunosuppressive drug, Mycophenolic Acid. Increasing government initiatives to promote TDM further boosted the growth of the market in the region.

Some of the major players operating: Roche AG, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Abbott Laboratories, Inc., Agilent Technologies, Inc., bioMerieux, Inc., Bayer AG, Alere, Inc among others. Several M&A's along with partnerships have been undertaken.